A novel, recombinant triple antigen hepatitis B vaccine (Hepacare®)

Intervirology

Volumn 44, Issue 2-3, 2001, Pages 88-97

  Page, M ^a,c   Jones, C D ^a   Bailey, C ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UCB PHARMA   (Belgium)

^c NONE   (United Kingdom)

Author keywords

Hepacare

Indexed keywords

ALUMINUM HYDROXIDE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; PROTEIN PRE S1; PROTEIN PRE S2; RECOMBINANT HEPATITIS B VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VITRONECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CHIMPANZEE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; EUKARYOTIC CELL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE;

ANIMALS; CLINICAL TRIALS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HLA ANTIGENS; HUMANS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PAN TROGLODYTES; PROTEIN PRECURSORS; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EUKARYOTA; HEPATITIS B VIRUS; PAN (APE);

EID: 0034880488     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050036     Document Type: Article

References (72)

1. Immune response to the hepatitis B virus: Infection, animal models, vaccination
2. Hepatitis B virus vaccines
3. Hepatitis B virus biology
4. Hepatitis B virus vaccine: A current appraisal of human plasma-derived vaccines
5. Human hepatitis B vaccine from recombinant yeast
6. Production and immunological analysis of recombinant hepatitis B vaccine
7. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine
8. The human immune response to hepatitis B surface antigen
9. Normal HBsAg presentation and T-cell defect in the immune response of nonresponders
10. T cell and antibody characterisation of a new recombinant pre-S1, pre-S1 and SHBs antigen-containing hepatitis B vaccine: Demonstration of superior anti-SHBs antibody induction in responder mice
11. The influence of host factors and immunogenetics on lymphocyte responses to Hepagene vaccination
12. Evaluation of B and T cell responses in chimpanzees immunized with Hepagene, a hepatitis B vaccine containing pre-S1, pre-S2 and S gene products
13. A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: Protective efficacy in chimpanzees
14. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus
15. Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralising and protective
16. Protective effect of a synthetic peptide comprising the complete pre-S2 region of the hepatitis B virus surface protein
17. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): A pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg
18. A single 10-residue pre-S(1) peptide can prime T cell help for antibody production to multiple epitopes within the pre-S(1), pre-S(2) and S regions of HBsAg
19. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines
20. Enhanced immunogenicity of the pre-S region of Hepatitis B surface antigen
21. Distinct H-2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region
22. Complete genomes, phylogenetic relatedness and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes
23. Surface proteins of hepatitis B virus
24. The hepatitis B virus
25. HBs antigen subtypes
26. New hepatitis B surface antigen subtype inside the ad category
27. Distribution of HBsAg subtypes in the world
28. Hepatitis B vaccine in medical staff of hemodialysis units: Efficacy and subtype cross-protection
29. A polypeptide containing 55 amino acid residues coded by the pre-S region of hepatitis B virus deoxyribonucleic acid bears the receptor for polymerized human as well as chimpanzee albumins
30. Current and future hepatitis B vaccines
31. Pre-S containing HBsAg particles from Saccharomyces cerevisae: Production, antigenicity and immunogenicity
32. Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine)
33. Phase II study of recombinant HB vaccine containing the S and pre-S2 antigens
34. Does the pre-S2 have the same effect on improving the HBV immune response compared to pre-S1?
35. Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): Phase 1, 2 and 3 clinical testing
36. A new pre-S containing recombinant hepatitis B vaccine and its effect on non-responders: A preliminary observation
37. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: Randomised double blind dose response study
38. Immune response to hepatitis B virus protein: Relevance of the murine model
39. Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination
40. Virus-neutralising antibodies to Hepatitis B virus: The nature of an immunogenic epitope on the S gene peptide
41. Qualitative analysis of the humoral immune response to the 'a' determinant of HBs antigen after inoculation with plasma-derived or recombinant vaccine
42. A study of the antigenicity and immunogenicity of a new hepatitis B vaccine using a panel of monoclonal antibodies
43. Concurrently circulating hepatitis B surface antigen and heterotypic anti-HBs antibody
44. The development of HBsAg positive hepatitis despite the previous existence of antibody to HBsAg
45. Hepatitis B vaccine. Demonstration of efficacy in a controlled clinical trial in high-risk population in the United States
46. Clinical evaluation of a recombinant hepatitis B vaccine
47. Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: An experimental study in the chimpanzee
48. A multi-centre, double-blind, parallel-group comparative study to assess the efficacy and safety of Hepagene and Engerix B in subjects with a proven inadequate response to prior vaccination
49. A multi-centre, double-blind, parallel-group comparative study to assess the efficacy and safety of a single dose of either Hepagene or Engerix B in subjects with an inadequate response to previous vaccination with an S-containing hepatitis B vaccine
50. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers
51. A comparative trial of standard or high dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders
52. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccine
53. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumour necrosis factor alpha
54. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing
55. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products
56. Dendritic cells and immune based therapies
57. The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants
58. The Hepatitis B virus core and antigens elicit different Th cell subsets: Antigen structure can affect Th cell phenotype
59. Cellular immune responses of peripheral blood mononuclear cells to HBV antigens during chronic and acute HBV infection
60. Induction of T helper cell response to HBcAg in chronic hepatitis B: A major factor in activation of the host immune response to the hepatitis B virus
61. Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B
62. Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B
63. Direct ex-vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection
64. Viral clearance without destruction of infected cells during acute HBV infection
65. Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and independent pathways
66. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice
67. To kill or to cure: Options in host defence against viral infection
68. Human T cell response to the surface antigen of hepatitis B virus (HBsAg): Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen
69. In vitro T cell immune responses to the preS2 antigen of the hepatitis B virus envelope protein in preS2+S vaccine recipients
70. Characterisation of the T and B-cell response to a new recombinant pre-S1, pre-S2 and SHBs antigen containing hepatitis B vaccine (Hepagene); evidence for superior anti-SHBs antibody induction in responder mice
71. Specific vaccine therapy in chronic hepatitis B infection
72. Specific vaccine therapy in chronic hepatitis B: Induction of T cell proliferative responses specific for envelope antigens